The Foundation for the Institute of Oncology Research
signature
Prof. Franco Cavalli

President of the Foundation
Thank you for entering the website of the Foundation for the Institute of Oncology Research

Our Foundation currently manages three separate activities:
1.
IOR
Institute of Oncology Research
2.
IELSG
International Extranodal Lymphoma Study Group
3.
ICML
International Conference on Malignant Lymphoma
The Foundation was founded on 11.1.1999 as a Foundation for the Research and Treatment of Lymphoma in Tessin, mainly because the International Conference on Malignant Lymphoma in Lugano (ICML), from a humble beginning in 1981 had grown to such a size that it needed a legal and administrative body to continue to manage the event.

Slowly, the Foundation became associated with oncological research in Tessin, financing specific projects, principally in the field of malignant lymphoma. In particular, the Foundation played an important role in financing the development of the IELSG (International Extranodal Lymphoma Study Group) and also in supporting the database of the IOSI (Institute of Oncology of Southern Switzerland), a fundamental tool for identifying clinical research topics.

In 2011, the Foundation was obliged, for legal and administrative reasons, to take over the management of the research laboratories of the IOSI, situated in the building of the IRB (Institute of Research in Biomedicine) in Bellinzona, which from that moment on were renamed the Institute of Oncology Research (IOR).

This step was strongly advocated by the federal authorities, which in view of the high level of quality of the research, wanted to support the laboratories with federal subsidies. This however required the separation of the administration from that of the EOC (Ente Ospedaliero Cantonale) respectively of IOSI, to avoid the problem of federal funding to a cantonal institution.

This passage has also allowed a more flexible management of the IOR, which since then has had a very rapid development.

Since the management of the IOR has become the principal activity of the Foundation and so in order to create a parallel structure to that of the IRB, in 2018 it was decided to change the name of the Foundation, transforming it into "Foundation for the Institute of Oncology Research". This change was accepted by the Federal Institutions and the Foundation Control during 2018 and is now fully effective.
As you can see there is a lot to take in and I am sure that as you continue reading this site, you will be impressed by all that we have accomplished.

Personally, I am very proud of our achievements.
Official website:
www.ior.iosi.ch
The IOR (Institute of Oncology Research) started its activity in 2003 inside the building of the Institute for Research in Biomedicine (IRB) in Bellinzona. In a few years, IOR researchers attained worldwide recognition through the publication of ground breaking research with a high impact in international leading scientific journals.

Furthermore the researchers were able to obtain important financial contributions both in Switzerland and from the extremely selective European Union programmes.

This excellent quality level has been recognized first by the State Secretariat for Education, Research and Innovation (SEFRI), which has granted to IOR the much sought-after federal subsides and later by the Università della Svizzera italiana (USI), which affiliated the IOR in 2016 within the newly created Faculty of Biomedicine.

To date (2018) almost 70 people work in the laboratories of the IOR with an annual budget that is approaching the threshold of 10 million francs.
Scientific Board
Dalla Favera Riccardo (Chair)Columbia University, New York
Thalmann George Inselspital Bern
Hynes Nancy E. Friedrich Miescher Institute, Basel
Hallek Michael University of Cologne, Cologne
Cvitkovic Esteban Contract Research Organisation, Paris
Christofori Gerhard Institute of Biochemistry and Genetics, Basel
International Extranodal Lymphoma Study Group
Official website:
www.ielsg.org
The IELSG was born in 1996, when it became clear that only an international research group rather than single institutions can study extranodal lymphoma (which represent approximately 40% of all malignant lymphoma), due to the fact that outcomes are largely dependent on the localization of the primary lymphoma.
As these lymphoma can originate in all organs of our body, the various forms (cerebral, testicular, pulmonary, etc.) are relatively rare, creating the necessity for a large study group involving many institutions.

IELSG has enjoyed an enormous success: currently, under the coordination of Prof. Emanuele Zucca and the operational office located at the Institute of Oncology of Southern Switzerland (IOSI) in Bellinzona, almost 300 institutions on 4 continents participate in these studies, which have also generated about fifty scientific papers published in leading journals.
International Conference on Malignant Lymphoma (ICML)
Official website:
www.icml.ch
The ICML was organised for the first time in 1981: first every three years, since 2011 every two years. This conference has now become the main conference for all those involved in research or treatment of patients with malignant lymphoma.

Currently, for logistical reasons, we are obliged to limit the number of participants to 3'500, although many more would like to attend.

It is mainly thanks to ICML that the name of Lugano is now known worldwide in the field of medicine, to such an extent that the " Lugano Classification" is universally used for the evaluation of patients with this type of cancer.
Foundation Board of Trustees
Cavalli Franco
Board of directors
President

Born in Verscio, in 1942, he is Professor (full professor) of medical oncology at the Faculty of Medicine in Bern, Switzerland.

In 1978 he created the Cantonal Oncology Service in Tessin which in 1999 became the Institute of Oncology of Southern Switzerland (IOSI) in Bellinzona, Canton Tessin (Switzerland), an institute which encompasses medical oncology, radio-oncology, nuclear medicine, palliative care, haematology and an important research division and of which he was scientific director of oncology until 2017.

Franco Cavalli has an international reputation for the treatment and research of malignant lymphoma and new drugs.

In 1981 he organized in Lugano the first edition of the International Conference on Malignant Lymphoma (ICML). Until 2011 it was held every three years, starting in 2011 once every two years. It has become the most important congress worldwide on malignant lymphoma.

In 1990 he was the founder and chief editor until the year 2000 of Annals of Oncology, the leading European journal of medical oncology.

In 1996 he founded the International Extranodal Lymphoma Study Group (IELSG), which now comprises more than 200 institutions on 4 continents. IELSG is the leading cooperative group in the field of biological and clinical studies regarding extranodal lymphomas.

He has also been very active in the field of clinical evaluation of new anticancer drugs. The quality of his work has been recognised with 24 national and international awards, including the Petzcoller Award for his special dedication to oncology and the ESMO Lifetime Achievement Award.

He is an honorary professor at the Universities of Tianjin (China), Biskek (Kyrgyzstan), Managua (Nicaragua) and Havana (Cuba). He has published more than 600 articles in peer-reviewed journals and contributed to numerous books on cancer, including the Textbook of Medical Oncology, along with Stanley Kaye (London), Heine H. Hansen (Copenhagen) and James O. Armitage (Omaha, Nebraska) He is on the editorial board of several other journals.

Franco Cavalli was President of the Swiss Cancer League and is Chairman of the Scientific Committee of the European School of Oncology (ESO) and of the World Oncology Forum (WOF). He was President of the International Union Against Cancer (UICC) between 2006 and 2008. Since 2015, he has been a member of the WHO Committee for the selection of essential medicines for cancer.

He is currently president of the Foundation for the Institute of Oncology Research, based in Bellinzona, which manages the Institute of Oncology Research (IOR), the International Extranodal Lymphoma Study Group (IELSG) and the International Conference on Malignant Lymphoma (ICML).

Between 1995 and 2007 he was a member of the Swiss Parliament.

Noseda Giorgio
Board of directors
Vice-president

Born in Mendrisio, on July 14, 1938. He was Head of internal medicine at the Mendrisio Regional Hospital, cardiology at the Civic Hospital of Lugano and full professor (now emeritus) at the University of Bern. He has devoted himself with great commitment to the fight against cancer.

He was president of the Swiss Cancer League (1989-1992) and at the same time a member of the Board of Trustees of the Swiss Institute for Experimental Cancer Research (ISREC) in Lausanne. In 1996 he founded the Administrative Centre of the Swiss Cancer Organizations (Haus der Krebsliga) in Bern. He contributed to the creation of various institutions involved in the fight against cancer: in 1991 the Swiss Cancer Research Foundation, which he chaired until 2006; in 1999 the Oncosuisse Association, which he chaired until 2006; in 2007 the National Institute for Cancer Registration and Epidemiology (NICER), based at the University of Zurich, which he chaired until 2018.

From 2001 to 2012 he chaired the Swiss Bridge Foundation, which raises funds for cancer research. He is vice-president of the Ticino Foundation for Cancer Research (Lugano, since 1984), of the Foundation for the European School of Oncology (Bellinzona, since 1990) and of the Foundation for the Institute of Oncology Research (IOR), associated with the Faculty of Biomedicine of the Università della Svizzera italiana (USI). In 1997 he participated in the foundation of the Institute for Research in Biomedicine (IRB) in Bellinzona, associated with the Faculty of Biomedicine of the Università della Svizzera Italiana, and chaired it until 2012.

He was a member of the Gran Consiglio ticinese from 1975 to 1989: he chaired the Commission for Hospital Law, for which he was a speaker at the Parliament, which gave rise to the Ente Ospedaliero Cantonale in December 1982.

Author of numerous scientific publications. He is an honorary member of the Swiss Academy of Medical Sciences. For his activities in the field of cancer, he was awarded the Swiss Award in 2007 and received the Medal of the Swiss Cancer League in 2011.

Since 1999 he has been Vice-President and member of the Board of Directors of the Foundation for Research and Treatment of Lymphomas in Ticino, now the Foundation for the Institute of Oncology Research (IOR).

Cerny Thomas

Born in Nesslau (SG) in 1952

Compulsory and secondary schools

  • 1959-1963: Primarschule Bern
  • 1964-1972: Gymnasien in Feldkirch (A), Bern and Sarnen (CH)
  • 1972: Maturity type A

Medical studies

  • 1972-1978: Faculty of Medicine, Berne

Medical and Academic Career

  • 1979-1980: Pathologisches Institut der Universität Bern, Prof. H. Cottier
  • 1980-1981: Medizinische Abteilung, Regionalspital Burgdorf, Dr. H. Schütz
  • 1981-1982: Medizinische Poliklinik und Dialysestation der Univ. Bern, Prof. F. Reubi
  • 1982-1985: Medizinische Klinik der Universität Bern, Inselspital, Prof. W. Straub und Prof. H. Studer, with additional rotational internships in Cardiology, Hematology and Oncology
  • 1985-1986: Research Fellow of the EORTC, Department of Medical Oncology, University of Manchester, Christie Hospital and Patterson Institute, Prof. D. Crowther and Prof. N. Thatcher, with last post as Senior Lecturer.
  • 1986-1993: Oberarzt (Consultant) of the Institut für Medizinische Onkologie (IMO) der Universität Bern, Inselspital, Prof. K. W. Brunner
  • 1993-1997: Stv.-Chefarzt of the IMO (Direktor Prof. M.F. Fey) and Head of the Externer Konsiliardienst des Kantons Bern
  • 1995-1997: Head of Tumor Registry of Inselspital
  • 1998-2017: Head Dept. Medical Oncology and Haematology of Kantonsspital St. Gallen (KSSG) During this period for 6 years member of the hospital board of directors und director of the entire Dept. of Internal Medicine. Former Founder and President of the Scientific Board of the Institute of Medical Research KSSG until 2014
  • 2017: Prof. emeritus Universität Bern

Promotions/Diplomas

  • 1988: FMH Internal Medicine
  • 1997: FMH Medical Oncology (also ESMO certificat)
  • 1991: PD, Privatdozent der Univ. Bern, for Internal Medicine and Medical Oncology
  • 1995: Professor for Internal Medicine and Medical Oncology, University of Bern, Diploma in Palliative Oncology (KLS)

Actual National Functions

  • Acting President Stiftung Krebsforschung Schweiz (KFS)
  • Board-member Krebsliga Schweiz (KLS, Honorary-President)
  • Board-member Oncosuisse (Past-President)
  • Board-member of the Human Medicines Expert Committee (HMEC) of Swissmedic
  • Board member TOLREMO and ProteMediX (both ETH-University start-ups, Board membership for ProteoMedix; since 2019 cofounder of ProteoMediX)
  • Board-member and Vice President of APC-Society (Advanced Prostate Cancer)

Important Memberships

  • SAKK
  • Schweizerische Gesellschaft für Innere Medizin (SGIM)
  • Schweizerische Gesellschaft für Medizinische Onkologie (SGMO)
  • European Society for Medical Oncology (ESMO)
  • American Society of Clinical Oncology (ASCO)
  • International Association for the Study of Lung Cancer (IASLC)
Journals
  • Editor in chief: info@onkologie (Medinfo-Verlag)
  • Editorial Board: Oncology, Research and Treatment, Karger Verlag

Relevant Research Awards 1995: Robert Wenner Preis für Krebsforschung (CHF 150,000.)

Since 2020 he has been a member of the Foundation Board of the Foundation for the Institute of Oncology Research (IOR)

Erez Boas

Born in 1962, in Chur, Switzerland, he graduated in 1981 from the Liceo Cantonale (scientific lyceum) in Lugano, and continued his studies at the University of Geneva where he obtained a degree in mathematics in 1985 and, in 1987, a Ph.D. in mathematics.

From 1985 to 1990, he was an assistant at the same university, before moving to Harvard University where he was Benjamin Peirce Assistant Professor from 1990 to 1993. In 1993, he was appointed Full professor of mathematics at the University of Bordeaux, where he held several executive positions at the level of institute, faculty, commissions, programmes, doctoral committees and international scientific projects.

Prof. Erez was time and again a Board member of the University of Bordeaux 1, and was also vice-president of the university from 2005 to 2008. Prof. Erez is the author of numerous quality scientific publications and has regularly organized international activities in his subject field. He has great experience in the coordination of joint international projects in higher education.

As of September 1st, 2016, Prof. Boas Erez is Rector of the Università della Svizzera italiana.\nSince 2016 he has been a member of the Foundation Board of the Foundation for the Research and Treatment of Lymphomas in Ticino, now the Foundation for the Institute of Oncology Research (IOR).

Ferrari Paolo

Professor Paolo Ferrari is the current Head of the Medical Area of the Ente Ospedaliero Cantonale in Ticino and consultant physician in nephrology at the Ospedale Civico di Lugano. He obtained a degree and specialization in medicine at the University Hospital of Bern, achieving certification in internal medicine and nephrology, after specializing at the Inselsiptal Bern and obtained the certification of specialist in hypertension of the European Hypertension Society (ESH).

Professor Ferrari worked in Australia from 2003 to 2017, first in Perth, Western Australia, as Director of the Department of Nephrology at Fremantle Hospital and later in Sydney, where he was the Director of the Kidney Transplant Centre at Prince of Wales Hospital. He was the founding director of Australia's crossover and kidney transplant program. In 2015 he was awarded the Australian Legion of Honor (Officer of the Order of Australia) for his contributions to the development of kidney transplant treatment.

Professor Ferrari is the outgoing (2016-2017) president of the Australian and New Zealand Society of Nephrology (ANZSN) and is a member of several national and international professional committees, including ISN, ASN, EDTA, APSN and TTS and associate editor of numerous nephrology journals. He is assistant professor at the University of New South Wales in Sydney and full professor at the Università della Svizzera italiana.

He has established research programs in the vast areas of nephrology, including chronic renal disease and kidney transplantation, has an H index of 48 and has published over 200 articles in peer-reviewed journals.

Since 2018 he has been a member of the Foundation Board of the Foundation for the Institute of Oncology Research (IOR) and of the Foundation Board of the Transfusion Service of Southern Switzerland.

Ghielmini Michele
Board of directors

Compulsory and secondary school in Ticino.

Medical studies in Lausanne, postgraduate training in Ticino, Zurich, Bern, Basel, Manchester and Frankfurt.

Medical degree in 1985, doctorate in 1988, specialisation in internal medicine in 1993, specialisation in haemato-oncology in 1995.

Title of Privat Dozent at the University of Bern in 2001, title of Honorary Professor at the University of Bern in 2007.

Since 01.07.2007 Head of medical oncology at IOSI (Institute of Oncology of Southern Switzerland). Since 01.07.2011 health director of IOSI (Institute of Oncology of Southern Switzerland).

From 2001 to 2006 he was President of the Lymphoma Group at SAKK (Swiss Group for Clinical Research against Cancer), and was also President of several national and international studies in the field of lymphomas. For 15 years he was Director of the IOSI Stem Cell Transplantation Programme.

Member of the SAKK scientific committee, he was for years a member of the editorial board of "Annals of Oncology" and of the "editorial board" of Journal of Clinical Oncology. He has served as chairman of the ESMO Publishing Working Group, the ESMO Website working group and as chairman of the ESMO Educational Committee.

Since 1999 he has been a member of the Foundation Board of the Foundation for the Research and Treatment of Lymphomas in Ticino, now the Foundation for the Institute of Oncology Research (IOR).

Since 2019 he has been a member of the Board of Directors of the Foundation.

Gillessen Sommer Silke

Born in Niederdorf in 1965, she graduated in medicine at the University of Basel in 1990, where she received her doctorate in 1992. After working as an assistant physician at Thurgauisch-Schaffausch-Höhenklinik in Davos, she became an associate researcher in the department of inflammatory/autoimmune diseases at Hoffmann-La Roche in the United States. Active at Claraspital and Kantonsspital in Basel, she moved to the cantonal hospital of St. Gallen, where she obtained her specialization in internal medicine.

From 1998 to 2000 she stayed in the United States, working as a researcher at the Dana-Farber Cancer Institute in Boston. She then returned to the St. Gallen Cantonal Hospital, where she was head of the oncology/hematology department; there she obtained her specialization in medical oncology and was appointed head of service.

In 2006, she was awarded the qualification of Free Lecturer (PD) in Medical Oncology by the University of Bern, which in 2011 awarded her the title of Full Professor. Since 2018, her main activity has been in the field of teaching and research. She is a professor at the British University of Manchester in the Cancer Science Division, responsible for research into systemic therapy of genito-urological cancers, mentors and provides post-graduate training.

As far as research is concerned, she has published about 150 articles in peer-reviewed journals and has received considerable recognition for her research projects. She is considered a key opinion leader internationally in the field of prostate cancer and malignant genito-urinary diseases. She is a member of the main scientific committees and of the major associations of her speciality at national and international level. She is often called upon to speak at major international symposia.

Since 2019 she has been a member of the Foundation Board of the Foundation for the Institute of Oncology Research (IOR).

Jackson Olga
Secretary

Born in Prague in 1957, she emigrated with her parents to Switzerland in 1968.

She finished compulsory schooling and obtained a commercial diploma in Thun.

Between 1976 and 1978 she was employed as a secretary at the Department of Oncology, Inselspital Bern, under Prof. K. Brunner.

Between 1978 and 1980 she was employed as a secretary at the cantonal cancer service in Bellinzona.

Between 1978 and 1984 she was the special secretary to Professor F. Cavalli, president of the SAKK (Swiss Group for Clinical Research Against Cancer).

In 1981 she organized the first International Conference on Malignant Lymphoma (ICML) in Lugano, organizing the conference successively every 3 years until 2005.

From 1981 to 2010 she was scientific secretary of Prof. F. Cavalli for special tasks.

Since 1999 she has been the secretary of the Foundation for Research and Treatment of Lymphomas in Ticino, now the Foundation for the Institute of Oncology Research (IOR).

Malacrida Roberto

Raised in Bellinzona, he is married to Ferdinanda and father of Martina and Filippo.

He was head of Intensive Medicine in Lugano and was the doctor in charge of REGA-Ticino and the Green Cross of Bellinzona. He has taught clinical humanism as a full professor at the Department of Psychology at the University of Fribourg and intensive care medicine with clinical ethics as an associate professor at the Faculty of Medicine at the University of Geneva. He has 50 publications in "editorial control" journals, of which he is the first author and co-author of 3 articles in the New England Journal of Medicine.

He was president of the Swiss Society of Biomedical Ethics and member of the Central Ethics Commission of the Swiss Academy of Medical Sciences; co-founder and former vice-president of the Ethics Commission of the Ente Ospedaliero Cantonale (EOC). Member of the National Ethics Commission for Human Medicine. He is currently general secretary of the Sasso Corbaro Foundation, Director of the Journal for Medical Humanities, former co-responsible for the MAS in clinical ethics and Medical Humanities of SUPSI. Member of the Board of Directors of the EOC, he represents the Municipality of Bellinzona in the Board of Directors of the IOR.

Since 2017 he has been a member of the Foundation Board of the Foundation for the Research and Treatment of Lymphomas in Ticino, now the Foundation for the Institute of Oncology Research (IOR).

Marxer Florian
Board of directors

Born in St. Gallen in 1976, Florian Marxer graduated from high school in Feldkirch (Austria) in 1995. He studied law at the Universities of Innsbruck (Mag. iur. 2002), Strasbourg (Erasmus 1997/98), Yale (LL.M. 2005), Vaduz (specialisation course in Liechtenstein in company law 2006) and Zurich (Dr. iur. 2007). He has been admitted to advocacy in New York (since 2006) and Liechtenstein (since 2010) and is the author of several books and articles on Liechtenstein law. Florian Marxer is a partner in the law firm Marxer & Partner Rechtsanwälte (Vaduz) and a member of the board of directors of various companies and foundations, including VP Bank AG (Vaduz), Belvédère Asset Management AG (Glarus) and Alexander S. Onassis Public Benefit Foundation (Vaduz).

Since 2016 he has been a member of the Foundation Board of the Foundation for Research and Treatment of Lymphomas in Ticino, now the Foundation for the Institute of Oncology Research (IOR).

Since 2019 he has been a member of the Board of Directors of the Foundation.

Masullo Alba

Born in Saignelégier (Ct. Jura) in 1964, Alba Masullo graduated from high school in Lugano 1 in 1985, then - after a few years of university studies in medicine then abandoned - the Diploma in Psychology at the University of Lausanne in 2000 and the Master in Medical Humanities at the University of Insubria in Varese in 2004.

She worked in a reception centre for refugees of Caritas and several years in the field of human resources management at the employment offices, then 7 years as a consultant in professional integration of people with health damage at the office of invalidity insurance of the ct. Ticino. From 2003 to 2005 she was project manager for the implementation of the professional assessment centre for disability insurance in Gerra Piano.

Since 2005, she has been the director of the Ticino Cancer League and, in this capacity, a member of various working groups and commissions within the Swiss Cancer League and the cantonal administration, as well as a member of several Foundations and Societies linked to the research and/or care of people suffering from cancer and their families.

Since 2008, she has been a member of the Foundation Board of the Foundation for Research and Treatment of Lymphomas in Ticino, now the Foundation for the Institute of Oncology Research (IOR).

Pandolfi Elena Maria

Born in Capriasca in 1960, Elena Maria Pandolfi, after a first long working experience in business management as a managing director, obtained her doctorate in Italian linguistics at the University of Bern.

For over a decade she has been active in the Division of Culture and University Studies in research programmes in the linguistic-cultural field, gaining experience in the management of interdisciplinary projects at cantonal and federal level.

Since 2019 she has been a member of the Foundation Board of the Foundation for the Institute of Oncology Research (IOR).

Zürcher Giovanni
Board of directors
Treasurer

Born on 4.8.1960, Giovanni Zuercher obtained the Federal Certificate of Commerce in 1979, and after some language and professional internships abroad, in 1986 he obtained the AIBD (ICMA, International Capital Market Association) diploma in Montreux. In the same year he joined the Paribas group, performing various tasks in the field of Investment Banking and later in asset management, becoming first responsible for the Italian market and then Southern Europe for the whole group. In 2001, with the merger between BNP and PARIBAS, he was appointed to the general management of the new bank. Giovanni also served for several years as director of the PARVEST investment fund in Luxembourg. In 2005, with a number of partners, he founded Pentagram wealth management based in Lugano and Geneva and currently holds the position of CEO and member of the board of directors. In addition to the IOR Foundation, he is also a member of the board of some charitable foundations.

Since 1999 he has been the Treasurer and member of the Board of Directors of the Foundation for the Research and Treatment of Lymphomas in Ticino, now the Foundation for the Institute of Oncology Research (IOR).

Past members
Barazzoni Fabrizio1999 - 2019
Camponovo Emilio1999 - 2019
Canova Rosalba1999 - 2008
Foiada Sandro2017 - 2018
Goldhirsch Aron1999 - 2016
Maggini Carlo2011 - 2016
Mathis Nicola2014 - 2017
Mozzini Aris2014 - 2019
Rusconi Alessandro2011 - 2014
Zanetti Felice2011 - 2017